Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema

Trial Profile

Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs AKB 9778 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Proof of concept
  • Acronyms TIME-1
  • Sponsors Aerpio Therapeutics
  • Most Recent Events

    • 13 Feb 2014 Results published in Aerpio Therapeutics Media Release.
    • 13 Feb 2014 Results were presented at American Academy of Ophthalmology 2013, according to an Aerpio Therapeutics.
    • 06 Nov 2013 Status changed from active, no longer recruiting to completed, according to an Aerpio Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top